Beauty injectables will continue to gain ground over the next decade, opening up promise for growth in the dermocosmetics field too, but industry must grow purposefully, said Valérie Taupin, founder and CEO of Teoxane.  In January, this year, Swiss aesthetic medicine specialist Teoxane expanded its dermocosmetics line into the US, making the company's range of serums, repair balms, and post-procedure treatments available to physicians across the country for the first time. The company is selling its dermocosmetics products via a dedicated US office—a privately held entity of Teoxane.Founded in 2003, the privately-backed company offers a line of patented dermal fillers—all certified under the EU Medical Device Regulation, with some also FDA-approved—and a range of topical skincare products for use alongside treatments. Today, dermal fillers represent 95% of Teoxane's global business, available to physicians in more than 90 countries worldwide, while dermocosmetics represent just 5%, with products sold to physicians in just over 40 markets via clinics and Teoxane directly.Last year, Teoxane—still independently run—gained two points in market share worldwide across fillers and dermocosmetics, and today the company places third in the US dermal fillers market, with 11% of market share.Taupin said bringing dermocosmetics to the US will significantly boost growth for Teoxane, given the size of the category and desire among physicians to offer complementary products pre- and post-procedure. Taupin said the US alone represents 43% of the worldwide market for the direct-to-physicians sale of dermocosmetics.And this is part of a much bigger market.